Virtual Library
Start Your Search
J. Wang
Author of
-
+
P1.05 - Poster Session with Presenters Present (ID 457)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Early Stage NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.05-045 - Adjuvant Chemotherapy for Patients with Stage IB Non Small Cell Lung Cancer (ID 4565)
14:30 - 15:45 | Author(s): J. Wang
- Abstract
Background:
The prognosis of stage Ib non-small cell lung cancer (NSCLC) remains poor, there’re much controversy over the necessity of adjuvant chemotherapy to them. The aim of this study is to investigate the clinical characters influencing prognosis of the stage Ib non-small cell lung cancer (NSCLC) and to explore the indication of postoperative chemotherapy.
Methods:
In total, 569 stage IB patients with NSCLC who underwent surgical resection with or without adjuvant therapy were included in this study. Cox proportional-hazards ratios were used to identify independent prognostic factors for survival. Kaplan-Meier survival curves were calculated to estimate survival rates.
Results:
Adjuvant chemotherapy, tumor size and performance status were independent prognostic factors in the univariate and multivariate analyses. Patients with tumor greater than 4 cm and patients with good performance status benefitted from adjuvant chemotherapy. On the contrary, to the patients with tumor less or equal to 4 cm or patients without good performance status, giving adjuvant chemotherapy is not better than giving surgery alone. Figure 1 Figure 2
Conclusion:
Adjuvant chemotherapy, tumor size and performance status were closely correlated with survival in the stage Ib NSCLC, patients with tumor greater than 4 cm and patients with good performance status benefitted from adjuvant chemotherapy.
